Devonian Health Group Deepens Loss as It Pivots to Thykamine-Focused Drug Development

Devonian Health Group ( (TSE:GSD) ) just unveiled an announcement.

Devonian Health Group reported a net loss of $2.2 million for the quarter and $3.8 million for the first half ended January 31, 2026, reflecting the impact of expiring distribution agreements, notably for Dexlansoprazole, while ending the period with $1.3 million in cash and no debt. The company executed a one-for-sixty reverse share split, made key board and CFO appointments, and is pivoting toward a focused Thykamine-centric development strategy, prioritizing a pivotal radiodermatitis prevention trial and ongoing preclinical MASH and fibrosis studies that suggest potential anti-inflammatory and anti-fibrotic benefits.

Devonian is evaluating strategic alternatives for its Altius distribution business and exploring financing options to support its pipeline, underscoring a transition away from legacy revenue streams toward proprietary drug development. Recent preclinical data from a MASH mouse model indicate Thykamine may offer hepatoprotective effects comparable to an approved MASH therapy, bolstering the company’s scientific credibility alongside a recent peer-reviewed publication and potentially enhancing its long-term positioning in high-need inflammatory and liver disease markets.

More about Devonian Health Group

Devonian Health Group Inc. is a Québec-based clinical-stage biopharmaceutical company focused on developing innovative therapies for fibro-inflammatory diseases. Its lead product candidate, Thykamine, is being advanced across multiple indications, including radiodermatitis prevention and metabolic dysfunction-associated steatohepatitis (MASH), positioning the company within the anti-inflammatory and liver disease treatment markets.

Average Trading Volume: 1,294

Technical Sentiment Signal: Buy

Current Market Cap: C$34.29M

See more data about GSD stock on TipRanks’ Stock Analysis page.